Zhixiang Jintai (688443.SH): The application for the new drug Taliqiabai monoclonal antibody injection has been accepted for market approval.

Zhitong Finance and Economics APP News, Zhixiang Jintai (688443.SH) announced that recently, the company's teriflunomide injection (GR1802 injection) for adults with moderate to severe atopic dermatitis has achieved the primary endpoints in Phase III clinical trials. The company has submitted a new drug application for this indication to the China National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) and it has been accepted.